Dose-finding methods for Phase I clinical trials using pharmacokinetics in small populations.

about

Drugs for rare disorders.Design considerations for early-phase clinical trials of immune-oncology agents A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer

P2860

Q47334709-1B71647C-59D1-438C-82A3-0CC5B1D79DBB Q56334001-CCCCDC67-BCB6-4825-BF4B-FEF7F66955DE Q57162835-018C1EFC-4EBB-4DF4-A81C-5DE7D16F74EE

P2860

Dose-finding methods for Phase I clinical trials using pharmacokinetics in small populations.

Item

http://www.wikidata.org/entity/Q40283645

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Dose-finding methods for Phase ...... kinetics in small populations.

@en

type

Item

label

Dose-finding methods for Phase ...... kinetics in small populations.

@en

prefLabel

Dose-finding methods for Phase ...... kinetics in small populations.

@en

P1476

Dose-finding methods for Phase ...... kinetics in small populations.

@en

P2093

Corinne Alberti

http://www.w3.org/2001/XMLSchema#string

Emmanuelle Comets

http://www.w3.org/2001/XMLSchema#string

Frederike Lentz

http://www.w3.org/2001/XMLSchema#string

Nigel Stallard

http://www.w3.org/2001/XMLSchema#string

P2860

Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development

Dynamic calibration of pharmacokinetic parameters in dose-finding studies.

Pharmacokinetic/pharmacodynamic modeling in drug research and development.

Competing designs for phase I clinical trials: a review.

Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar.

Paving the critical path: how can clinical pharmacology help achieve the vision?

Dose escalation methods in phase I cancer clinical trials.

A survey of the way pharmacokinetics are reported in published phase I clinical trials, with an emphasis on oncology.

Defining a therapeutic window for the novel TGF-β inhibitor LY2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model.

Influence of the Size of Cohorts in Adaptive Design for Nonlinear Mixed Effects Models: An Evaluation by Simulation for a Pharmacokinetic and Pharmacodynamic Model for a Biomarker in Oncology

P304

804-825

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/BIMJ.201600084

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Sarah Zohar

Tim Friede

Moreno Ursino

P577

2017-03-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28321893

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

P932

5573988

http://www.w3.org/2001/XMLSchema#string

Dose-finding methods for Phase I clinical trials using pharmacokinetics in small populations.

about

P2860

P2860

Dose-finding methods for Phase I clinical trials using pharmacokinetics in small populations.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932